

# Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on Apr 11, 2025

## c-Myc (D3N8F) Rabbit mAb #13987

RRID:AB\_2631168

Type: Antibody

### Proper Citation

(Cell Signaling Technology Cat# 13987, RRID:AB\_2631168)

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2631168](http://antibodyregistry.org/AB_2631168)

**Proper Citation:** (Cell Signaling Technology Cat# 13987, RRID:AB\_2631168)

**Target Antigen:** c-Myc

**Host Organism:** rabbit

**Clonality:** monoclonal

**Comments:** Applications: W, IF-IC, F, ChIP, ChIP-seq

**Antibody Name:** c-Myc (D3N8F) Rabbit mAb #13987

**Description:** This monoclonal targets c-Myc

**Clone ID:** D3N8F

**Antibody ID:** AB\_2631168

**Vendor:** Cell Signaling Technology

**Catalog Number:** 13987

**Alternative Catalog Numbers:** 13987S

**Record Creation Time:** 20231110T034734+0000

**Record Last Update:** 20240725T080720+0000

### Ratings and Alerts

No rating or validation information has been found for c-Myc (D3N8F) Rabbit mAb #13987.

No alerts have been found for c-Myc (D3N8F) Rabbit mAb #13987.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 50 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [FDI Lab - SciCrunch.org](#).

Li B, et al. (2024) LncRNA XIST modulates miR-328-3p ectopic expression in lung injury induced by tobacco-specific lung carcinogen NNK both in vitro and in vivo. *British journal of pharmacology*, 181(15), 2509.

Ya A, et al. (2024) Cell Competition Eliminates Aneuploid Human Pluripotent Stem Cells. *bioRxiv : the preprint server for biology*.

Volegova MP, et al. (2024) The MYCN 5' UTR as a therapeutic target in neuroblastoma. *Cell reports*, 43(5), 114134.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. *Cancer cell*, 42(7), 1185.

Wang H, et al. (2023) Premature aging and reduced cancer incidence associated with near-complete body-wide Myc inactivation. *Cell reports*, 42(8), 112830.

Albuquerque-Bejar JJ, et al. (2023) MYC activation impairs cell-intrinsic IFN $\gamma$  signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer. *Cell reports. Medicine*, 4(4), 101006.

Zhang XL, et al. (2023) K235 acetylation couples with PSPC1 to regulate the m6A demethylation activity of ALKBH5 and tumorigenesis. *Nature communications*, 14(1), 3815.

Ram BM, et al. (2023) Detection of the DNA binding of transcription factors in situ at the single-cell resolution in cultured cells by proximity ligation assay. *STAR protocols*, 4(4), 102692.

Li G, et al. (2023) Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. *Cancer cell*, 41(2), 304.

Griger J, et al. (2023) An integrated cellular and molecular model of gastric neuroendocrine cancer evolution highlights therapeutic targets. *Cancer cell*, 41(7), 1327.

Xu M, et al. (2023) Heat shock factor 1 (HSF1) specifically potentiates c-MYC-mediated transcription independently of the canonical heat shock response. *Cell reports*, 42(6), 112557.

Liu H, et al. (2023) Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphoma. *eLife*, 12.

Wei Y, et al. (2023) N6-methyladenosine modification promotes hepatocarcinogenesis through circ-CDYL-enriched and EpCAM-positive liver tumor-initiating exosomes. *iScience*, 26(10), 108022.

Parmigiani E, et al. (2022) Interferon- $\gamma$  resistance and immune evasion in glioma develop via Notch-regulated co-evolution of malignant and immune cells. *Developmental cell*, 57(15), 1847.

Rashkovan M, et al. (2022) Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia. *Cancer discovery*, 12(3), 856.

Zhang ZL, et al. (2022) MicroRNA-101a-3p mimic ameliorates spinal cord ischemia/reperfusion injury. *Neural regeneration research*, 17(9), 2022.

Weng H, et al. (2022) The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. *Cancer cell*, 40(12), 1566.

Maneix L, et al. (2022) Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 (HDAC3) Stabilization and Chromatin Condensation. *Cancer research communications*, 2(12), 1693.

Zhang D, et al. (2022) Yap-Myc signaling induces pancreatic stellate cell activation through regulating glutaminolysis. *Experimental cell research*, 411(1), 113000.

Michalek S, et al. (2022) LRH-1/NR5A2 interacts with the glucocorticoid receptor to regulate glucocorticoid resistance. *EMBO reports*, 23(9), e54195.